FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004273407> ?p ?o ?g. }

• W2004273407 endingPage "660" @default.
• W2004273407 startingPage "656" @default.
• W2004273407 abstract "The p53 tumour suppressor is either mutated or inactivated by other alterations in most human cancers. Two papers in this issue show that even brief reactivation of the endogenous p53 genes in established tumours can cause cancer regression in some animal models. In some tumours, p53 reactivation causes cellular senescence associated with an innate immune response that contributes to tumour clearance. These experiments used gene manipulation to alter p53 levels, but they lend further support to the idea that p53-boosting drugs could be a useful form of cancer treatment. One of two papers showing that reactivation of the endogenous p53 tumour suppressor genes in established tumours causes cancer regression. In some tumours, p53 reactivation causes cellular senescence associated with an innate immune response that contributes to tumour clearance. Although cancer arises from a combination of mutations in oncogenes and tumour suppressor genes, the extent to which tumour suppressor gene loss is required for maintaining established tumours is poorly understood. p53 is an important tumour suppressor that acts to restrict proliferation in response to DNA damage or deregulation of mitogenic oncogenes, by leading to the induction of various cell cycle checkpoints, apoptosis or cellular senescence1,2. Consequently, p53 mutations increase cell proliferation and survival, and in some settings promote genomic instability and resistance to certain chemotherapies3. To determine the consequences of reactivating the p53 pathway in tumours, we used RNA interference (RNAi) to conditionally regulate endogenous p53 expression in a mosaic mouse model of liver carcinoma4,5. We show that even brief reactivation of endogenous p53 in p53-deficient tumours can produce complete tumour regressions. The primary response to p53 was not apoptosis, but instead involved the induction of a cellular senescence program that was associated with differentiation and the upregulation of inflammatory cytokines. This program, although producing only cell cycle arrest in vitro, also triggered an innate immune response that targeted the tumour cells in vivo, thereby contributing to tumour clearance. Our study indicates that p53 loss can be required for the maintenance of aggressive carcinomas, and illustrates how the cellular senescence program can act together with the innate immune system to potently limit tumour growth." @default.
• W2004273407 created "2016-06-24" @default.
• W2004273407 creator A5003347599 @default.
• W2004273407 creator A5025451142 @default.
• W2004273407 creator A5027828146 @default.
• W2004273407 creator A5038427629 @default.
• W2004273407 creator A5052075637 @default.
• W2004273407 creator A5080940311 @default.
• W2004273407 creator A5081028472 @default.
• W2004273407 creator A5091821891 @default.
• W2004273407 date "2007-01-24" @default.
• W2004273407 modified "2023-10-18" @default.
• W2004273407 title "Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas" @default.
• W2004273407 cites W1483388049 @default.
• W2004273407 cites W1551102474 @default.
• W2004273407 cites W1930421942 @default.
• W2004273407 cites W1970249544 @default.
• W2004273407 cites W1982395176 @default.
• W2004273407 cites W1996949194 @default.
• W2004273407 cites W2001733842 @default.
• W2004273407 cites W2008887283 @default.
• W2004273407 cites W2009895779 @default.
• W2004273407 cites W2018116689 @default.
• W2004273407 cites W2023545773 @default.
• W2004273407 cites W2045264627 @default.
• W2004273407 cites W2045814034 @default.
• W2004273407 cites W2067117191 @default.
• W2004273407 cites W2080769506 @default.
• W2004273407 cites W2087404852 @default.
• W2004273407 cites W2092902276 @default.
• W2004273407 cites W2097010979 @default.
• W2004273407 cites W2097933346 @default.
• W2004273407 cites W2100894466 @default.
• W2004273407 cites W2101091611 @default.
• W2004273407 cites W2101538557 @default.
• W2004273407 cites W2107866742 @default.
• W2004273407 cites W2133898735 @default.
• W2004273407 cites W2137257146 @default.
• W2004273407 cites W2149569216 @default.
• W2004273407 cites W2150740687 @default.
• W2004273407 cites W2154799239 @default.
• W2004273407 cites W2162119603 @default.
• W2004273407 cites W2164022766 @default.
• W2004273407 doi "https://doi.org/10.1038/nature05529" @default.
• W2004273407 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4601097" @default.
• W2004273407 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17251933" @default.
• W2004273407 hasPublicationYear "2007" @default.
• W2004273407 type Work @default.
• W2004273407 sameAs 2004273407 @default.
• W2004273407 citedByCount "2085" @default.
• W2004273407 countsByYear W20042734072012 @default.
• W2004273407 countsByYear W20042734072013 @default.
• W2004273407 countsByYear W20042734072014 @default.
• W2004273407 countsByYear W20042734072015 @default.
• W2004273407 countsByYear W20042734072016 @default.
• W2004273407 countsByYear W20042734072017 @default.
• W2004273407 countsByYear W20042734072018 @default.
• W2004273407 countsByYear W20042734072019 @default.
• W2004273407 countsByYear W20042734072020 @default.
• W2004273407 countsByYear W20042734072021 @default.
• W2004273407 countsByYear W20042734072022 @default.
• W2004273407 countsByYear W20042734072023 @default.
• W2004273407 crossrefType "journal-article" @default.
• W2004273407 hasAuthorship W2004273407A5003347599 @default.
• W2004273407 hasAuthorship W2004273407A5025451142 @default.
• W2004273407 hasAuthorship W2004273407A5027828146 @default.
• W2004273407 hasAuthorship W2004273407A5038427629 @default.
• W2004273407 hasAuthorship W2004273407A5052075637 @default.
• W2004273407 hasAuthorship W2004273407A5080940311 @default.
• W2004273407 hasAuthorship W2004273407A5081028472 @default.
• W2004273407 hasAuthorship W2004273407A5091821891 @default.
• W2004273407 hasBestOaLocation W20042734072 @default.
• W2004273407 hasConcept C104317684 @default.
• W2004273407 hasConcept C121608353 @default.
• W2004273407 hasConcept C134018914 @default.
• W2004273407 hasConcept C134935766 @default.
• W2004273407 hasConcept C143425029 @default.
• W2004273407 hasConcept C16613235 @default.
• W2004273407 hasConcept C179185449 @default.
• W2004273407 hasConcept C203014093 @default.
• W2004273407 hasConcept C2778264664 @default.
• W2004273407 hasConcept C29537977 @default.
• W2004273407 hasConcept C502942594 @default.
• W2004273407 hasConcept C522857546 @default.
• W2004273407 hasConcept C54355233 @default.
• W2004273407 hasConcept C552990157 @default.
• W2004273407 hasConcept C555283112 @default.
• W2004273407 hasConcept C86803240 @default.
• W2004273407 hasConcept C95444343 @default.
• W2004273407 hasConcept C96232424 @default.
• W2004273407 hasConceptScore W2004273407C104317684 @default.
• W2004273407 hasConceptScore W2004273407C121608353 @default.
• W2004273407 hasConceptScore W2004273407C134018914 @default.
• W2004273407 hasConceptScore W2004273407C134935766 @default.
• W2004273407 hasConceptScore W2004273407C143425029 @default.
• W2004273407 hasConceptScore W2004273407C16613235 @default.
• W2004273407 hasConceptScore W2004273407C179185449 @default.
• W2004273407 hasConceptScore W2004273407C203014093 @default.

• next